AtaiBeckley Inc. announced it has satisfied a key condition for its pending acquisition by Eli Lilly and Company by clearing the U.S. antitrust review. The company also provided positive updates on regulatory reviews in the United Kingdom and Australia, advancing the planned merger.
Key Details
- U.S. Antitrust Clearance: The waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act expired on August 28, 2026, allowing the merger to proceed under U.S. antitrust law.
- International Regulatory Progress: The UK's Competition and Markets Authority indicated on August 21, 2026, that it had no further questions. The Australian Competition and Consumer Commission cleared the transaction, with a final waiting period set to expire on September 10, 2026.
- Merger Background: The updates relate to the previously announced merger agreement from July 15, 2026, under which Eli Lilly will acquire ATAI.